Tags:BioTechDevelopmentInformationNewsPersonalPlatformProductTechnology
Argos is focused on the treatment of metastatic cancers and chronic infections using a proprietary platform technology that stimulates immune cells with messenger RNA. The company’s lead product is for the personalized treatment of advanced renal cell carcinoma and is in phase III clinical development. A second product for therapeutic vaccination in HIV is in phase II development. Argos has also developed an interferon-neutralizing antibody for systemic lupus and has developed a CD83 Soluble Protein for Transplant Rejection/ Autoimmune Disorders in late preclinical development. Argos is listed on Nasdaq and traded under the symbol ARGS.
Location: United States, Durham
Total raised: $301.4M

Investors 2

Funding Rounds 7

DateSeriesAmountInvestorsDeal News
11.03.2016-$60M--
20.11.2013Series E$17.5M--
26.08.2013Series E$42.5M--
24.04.2012Series D$25M--
29.07.2011IPO$86M--
24.11.2008Series C$35.2M--
23.04.2008Series C$35.2M--

Mentions in press and media 20

DateTitleDescriptionCategoryAuthorSource
10.01.2018Lummy Inve...Argos Therapeutics Inc., biote...--citybizlis...
29.06.2016The biotec...There was a time af­ter the 20...FinancingJohn Carro...endpts.com...
11.03.2016Argos Ther...Argos Therapeutics, Inc. (Nasd...--forbion.co...
20.11.2013Argos Ther...Argos Therapeutics Inc., a Dur...Uncategori...-finsmes.co...
20.11.2013Argos Ther...Argos Therapeutics Inc., a bio...--forbion.co...
30.08.2013Argos Ther...Argos Therapeutics Inc., a bio...--forbion.co...
28.08.2013Argos Ther...Argos Therapeutics Inc., a Dur...funding U...-finsmes.co...
26.08.2013Argos Ther...Argos Therapeutics Inc., a bio...--forbion.co...
15.01.2013Personaliz...CEO Jeff Abbey told MedCity Ne...--medcitynew...
08.06.2012Experiment...Argos had planned to support i...--medcitynew...
Show more